Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This single arm, open-label study will evaluate the efficacy of Lutathera (177Lu-DOTATATE)
administered intravenously every 8 weeks for a total of 4 doses in patients with progressive
WHO I-III or residual high-risk Ga-DOTATATE PET-MRI positive meningioma. Ga-DOTATATE PET-MRI
scans will be obtained prior to initiation of Lutathera treatment and 6 months after the
initiation of Lutathera treatment. The latter will be performed within the 14 days prior to
the last dose of Lutathera treatment.